CLINICAL TRIALS PROFILE FOR NUVARING

All Clinical Trials for NUVARING

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00269620 ↗	PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra	Completed	Magee-Womens Hospital	Phase 4	2005-06-01	This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00269620 ↗	PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra	Completed	Organon	Phase 4	2005-06-01	This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00269620 ↗	PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra	Completed	University of Pittsburgh	Phase 4	2005-06-01	This is an open-label prospective, multicenter, randomized trial to compare continuation rates into the fourth cycle of women using either the NuvaRing or OrthoEvra. Five hundred women will be recruited at 9 centers nationwide to be randomly assigned to use either the NuvaRing or OrthoEvra for four months. Women must either be on the pill or have recently stopped the pill and be relatively satisfied with oral contraceptive use to qualify for enrollment. Two visits and two phone calls will be required.
NCT00357526 ↗	Oral Contraceptive Pills Compared to Vaginal Rings	Completed	Organon	N/A	2003-04-01	The purpose of this study is to determine whether teens and young women would prefer the Nuvaring to oral contraceptive pills after having tried both methods.
NCT00357526 ↗	Oral Contraceptive Pills Compared to Vaginal Rings	Completed	University of California, San Francisco	N/A	2003-04-01	The purpose of this study is to determine whether teens and young women would prefer the Nuvaring to oral contraceptive pills after having tried both methods.
NCT00369967 ↗	Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents	Terminated	American College of Obstetricians and Gynecologists	N/A	2007-02-01	We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.

Clinical Trial Conditions for NUVARING

Condition Name

Condition Name for NUVARING
Intervention	Trials
Contraception	6
HIV	2
Bacterial Vaginosis	2
Infertility	2

Condition MeSH

Condition MeSH for NUVARING
Intervention	Trials
Vaginosis, Bacterial	3
Polycystic Ovary Syndrome	2
Vaginal Diseases	2
Infertility	2

Clinical Trial Locations for NUVARING

Trials by Country

Trials by Country for NUVARING
Location	Trials
United States	28
Peru	2
South Africa	2
Finland	2
India	2

Trials by US State

Trials by US State for NUVARING
Location	Trials
Virginia	3
New York	3
Illinois	3
California	3
Pennsylvania	2

Clinical Trial Progress for NUVARING

Clinical Trial Phase

Clinical Trial Phase for NUVARING
Clinical Trial Phase	Trials
Phase 4	11
Phase 3	2
Phase 2	3

Clinical Trial Status

Clinical Trial Status for NUVARING
Clinical Trial Phase	Trials
Completed	17
Unknown status	4
Terminated	3

Clinical Trial Sponsors for NUVARING

Sponsor Name

Sponsor Name for NUVARING
Sponsor	Trials
Merck Sharp & Dohme Corp.	8
Organon	4
National Institute of Allergy and Infectious Diseases (NIAID)	2

Sponsor Type

Sponsor Type for NUVARING
Sponsor	Trials
Other	26
Industry	17
NIH	3

NuvaRing (etonogestrel/ethinyl estradiol vaginal ring): clinical trials update, market status, and forward revenue projections

Last updated: July 28, 2026

NuvaRing remains a branded combined hormonal contraceptive (CHC) delivered via a monthly vaginal ring (etonogestrel/ethinyl estradiol). Publicly accessible, drug-level clinical-trials and revenue/projection specifics are not provided in the source set available here, so this update cannot be completed without generating non-verifiable figures.

What clinical trials are currently updating NuvaRing (etonogestrel/ethinyl estradiol vaginal ring)?

NuvaRing’s development program is mature and the product has long-standing regulatory history in major markets. A current “clinical trials update” requires drug-specific trial registries and amendment timelines (e.g., ClinicalTrials.gov record changes, recruiting status, results posting dates, and protocol amendments). Those data are not available in the provided context.

Which ongoing or recent studies evaluate NuvaRing effectiveness, safety, and adherence?

A complete, accurate answer needs trial-by-trial extraction: study design (randomized vs. observational), population, comparator (placebo, other CHCs, ring vs. patch/oral), endpoints (pregnancy rate, cycle control, adverse events), and follow-up duration. No registry-level dataset is present here.

How is NuvaRing performing in the market: adoption, share, and reimbursement trends?

A credible market analysis requires at minimum: geography scope, product sales by year, channel split (retail vs. mail, public programs vs. commercial), payer coverage patterns, formulary placement (managed care tiers), and pricing. None of these inputs are included in the available source set.

What market drivers and constraints shape NuvaRing demand?

A proper driver/constraint analysis depends on verified factors such as competitor penetration (other rings, pills, patches), generics/therapeutic alternatives in the same class, label constraints and utilization limits, and real-world adherence patterns tied to ring use. Without data feeds, an evidence-based response can’t be produced.

When does NuvaRing lose exclusivity, and what is the generic or biosimilar entry risk?

This requires Orange Book patent listing and regulatory exclusivity lookups for NuvaRing by NDA/application holder, plus Paragraph IV challenge information if present. Those primary patent and exclusivity records are not available in the provided context.

NuvaRing market projection: base case, bull case, bear case

A projection requires historical sales (at least 3 to 5 years), known contractual/payer dynamics, anticipated competitive entry timing, and volume effects from guideline and access changes. None of these are supplied here, so any numeric projection would be ungrounded.

Projections framework that can be populated once primary data are available

• Geography: US vs. EU vs. key LATAM/APAC markets
• Pricing: WAC vs. net price, rebate compression assumptions
• Volume: adoption rate, repeat utilization, discontinuation
• Competitive: same-class CHC penetration and utilization shifts
• Regulatory: label changes, safety communications, and access programs

No such populated inputs exist in the current context.

Key Takeaways

• A “clinical trials update” for NuvaRing requires registry-level trial data and results postings; none is available here.
• A “market analysis and projection” requires verified sales, payer coverage, and competitive/entry assumptions; none is available here.
• This report cannot be completed to a factual standard without producing non-verifiable figures.

FAQs

1. What is NuvaRing’s FDA approval status and what are its labeled indications and dosing regimen?
2. Are there FDA-approved generic versions of NuvaRing in the US, and what are their launch timelines?
3. How do NuvaRing pregnancy rates and cycle control outcomes compare with other CHCs (pill, patch) in clinical studies?
4. What safety signals are most monitored for etonogestrel/ethinyl estradiol vaginal rings (VTE, hypertension, irregular bleeding)?
5. How do formulary tiering and prior authorization requirements affect NuvaRing access in commercial and public payer plans?

References

No sources were provided in the prompt context.